Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Dividend Declaration

6 Feb 2024 11:07

RNS Number : 1954C
Maven Income and Growth VCT 3 PLC
06 February 2024
 

 

Maven Income and Growth VCT 3 PLC

 

Proposed Final Dividend

 

On 18 December 2023, the Directors of Maven Income and Growth VCT 3 PLC ("the Company") announced that the unaudited net asset value of the Company as at 30 November 2023 was 52.48p per Ordinary Share.

 

The Directors propose that a final dividend of 2.15p per Ordinary Share, in respect of the year ended 30 November 2023, be paid on 3 May 2024 to Shareholders on the register at close of business on 22 March 2024.

 

As Shareholders will be aware from recent Annual and Interim Reports, decisions on distributions take into consideration a number of factors, including the availability of surplus revenue, the realisation of capital gains, the adequacy of distributable reserves and the VCT qualifying level. The Board and the Manager recognise the importance of tax-free distributions to Shareholders and, subject to the conditions set out above, will seek, as a guide, to pay an annual dividend that represents 5% of the NAV per share at the immediately preceding year end. This final dividend will bring total distributions for the financial year to 2.65p per Ordinary Share, representing an annual yield of 4.62%.

 

Since the Company's launch, and after receipt of this final dividend, a total of 99.72p per share will have been distributed in tax-free dividends. It should be noted that the effect of paying dividends is to reduce the NAV of the Company by the total cost of the distribution.

 

 

Dividend Investment Scheme

The Company has in place a Dividend Investment Scheme (DIS) through which Shareholders may elect to have their dividend payments used to apply for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax reliefs applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances. Terms & conditions of the scheme, together with a mandate form, are available from the Company's webpage at: mavencp.com/migvct3.

Shareholders who have not previously applied to participate in the DIS and who wish to do so in respect of the dividend payable on 3 May 2024, should ensure that a mandate form is received by the Company's Registrar, The City Partnership (UK) Limited, prior to the dividend election date of 12 April 2024. Election to participate in the DIS can also be made through the Registrar's online investor hub at: maven-cp.cityhub.uk.com.

 

Further to the information disclosed above, the Directors confirm that they are satisfied that all inside information (as defined by Article 7 of the Market Abuse Regulation (596/2014/EU)) that the Directors and the Company may have in their possession relating to the Company during the 30 day closed period leading up to the announcement of its annual results for the year ended 30 November 2023 has been or will be notified to a regulatory information service.

 

Issued on behalf of the Board

Maven Capital Partners UK LLP

Company Secretary

6 February 2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVEAFAKEELLEFA
Date   Source Headline
20th May 202610:00 amRNSAdmission of Further Securities to Trading
15th May 202610:05 amRNSIssue of Equity - Dividend Investment Scheme
12th May 20263:35 pmRNSUnaudited NAV - Dividend Investment Scheme
8th May 20267:00 amRNSTransaction in Own Shares
30th Apr 20261:30 pmRNSResult of AGM
30th Apr 202610:54 amRNSAdmission of Further Securities to Trading
29th Apr 202612:28 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:19 amRNSAdmission of Further Securities to Trading
14th Apr 202611:07 amRNSIssue of Equity
8th Apr 20269:28 amRNSAdmission of Further Securities to Trading
25th Mar 202610:54 amRNSAdmission of Further Securities to Trading
24th Mar 20265:32 pmRNSAnnual Financial Report
24th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20264:36 pmRNSNet Asset Value(s)
27th Feb 20265:01 pmRNSTransaction in Own Shares
27th Feb 20267:00 amRNSUnaudited NAV and Dividend Declaration
18th Feb 20264:52 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:05 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:02 amRNSDirector/PDMR Shareholding
17th Feb 202611:00 amRNSDirector/PDMR Shareholding
17th Feb 202610:55 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:03 amRNSAdmission of Further Securities to Trading
16th Jan 20269:42 amRNSIssue of Equity
14th Jan 20262:35 pmRNSUnaudited NAV - Dividend Investment Scheme
16th Dec 202510:20 amRNSIssue of Equity
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20254:47 pmRNSResult of General Meeting
28th Oct 20254:24 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:08 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:13 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:30 pmRNSHalf-year Report
22nd Jul 20254:49 pmRNSTransaction in Own Shares
16th Jul 20257:08 amRNSStatement re Offer for Subscription
10th Jul 20254:46 pmRNSStatement re Unaudited NAV and Interim Dividend
15th May 20253:57 pmRNSTransaction in Own Shares
9th May 20259:54 amRNSDirector/PDMR Shareholding
9th May 20259:51 amRNSIssue of Equity
6th May 202511:53 amRNSIssue of Equity
2nd May 20251:11 pmRNSAudited NAV - Dividend Investment Scheme
1st May 20253:15 pmRNSResult of AGM
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:17 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.